Nej till Zolgensma i Sverige

Zolgensma (onasemnogene abeparvovec) vid svårt muskelatrofi fick ett nej i Sverige. Läkemedlet är för dyrt ( 20 miljoner kronor). Det finns liten data om effektiva långsiktiga effekter. NT-rådets fortsätter att rekommendera standardterapi med Spinraza till barn under 18 år

Till dess att NT-rådet kan göra en sammanvägd bedömning och avge en rekommendation, rekommenderas regionerna att avvakta med införande av Zolgensma för att undvika införande på osäkra grunder och en ojämlik hantering i landet. Vid nydiagnostiserad SMA där det bedöms angeläget med snabb behandlingsstart hänvisas till rådande rekommendation för Spinraza.

Mer information på NT-rådet

Läs rekommendationen

Publicerat av

Liz

Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg Instagram

6 reaktioner till “Nej till Zolgensma i Sverige”

  1. At the beginning of 2020 in Germany, three children lost their fight against of SMA1 (5.6 years), despite treatment with Spinraza.
    I ask, what happens when a child dies prematurely and has been treated with Zolgensma?
    What happens to all the lot of money you paid for a life-extended drug?

    These are things, this needs to be clarified.

  2. Gute Sache, da hat Schweden was gutes entschieden. 👍👍👍 Irgendwo muss man Grenzen setzen, schließlich zahlen das auch die Bürger mit. Der Kuchen wird nicht größer , stattdessen werden die Kuchenteile für andere Patienten kleiner. Das gilt auch bei uns Krankenversicherte.

    Unsere Krankenkassen werden sich das erst jetzt nicht mehr leisten können aufgrund der Coronapandemi.

    Mir fehlt da jedes Verständnis bei dem Preis, so wenig Daten bzw, Bilddaten, zu wenige Dokumentation. Der einzige die sich freuen ist die Firma.
    Hoffendlich bleibt Deutschland bei dem Standardtherapie, man muss nicht zu alles ja sagen.

  3. More transparency about development costs, more evidence that it really helps. At the beginning had been pushing a drug, but missing the full data report. Other medication like Spinraza or Risdiplam show more study data. That is good that countries like Sweden drive a different course. One have to stop such high-priced drugs that show little data first. After all the citizens pay the bill .

  4. Sweden you doing a wise decision. There is simply too little data on the long-term effect. In the past, the company was not good in management in my eyes. When I think of the confused approval in America, or the global access program, which was like a lottery.

    Unfortunately said Gernany yes to this drug. Other people who fight for their therapies, she get not. The community must be able to pay for it. We can no longer afford such expensive therapies in the long run. The pieces of cake are getting smaller. The winners are companies and their shareholders.

  5. This is good Sweden stands to the standard therapy with Spinraza. I see it like everyone else here. Too little real visual documentation, too little reality data. The study is said to have been running for 3 years? I lack the true documentation. Risdiplam has more realistic data there. Which are now already highly regarded. I am not convinced enough about this drug.

Kommentarer inaktiverade.